Yahoo
NYSE - BOATS Real Time Price USD

Bristol-Myers Squibb Company (BMY)

57.62 -0.94 (-1.61%)
At close: June 30 at 4:00:02 PM EDT
57.82 +0.20 (+0.35%)
Overnight: 2:29:39 AM EDT
Trade BMY on Coinbase
Dividend
BMY announced a cash dividend of $0.63 with an ex-date of Jul. 2, 2026
Chart Range Bar
Loading chart for BMY
Chart does not reflect overnight price.

News headlines Bristol Myers Squibb (BMY) has been reclassified into value and defensive indexes, reflecting a shift in investor sentiment. A congressional probe into clinical trials in China raises regulatory concerns, while analysts caution about potential risks from Medicare drug price negotiations. The company is set to release its earnings on July 30, 2026, amid mixed market reactions.

Bristol Myers Squibb (BMY) has been reclassified into value and defensive indexes, reflecting a shift in investor sentiment. A congressional probe into clinical trials in China raises regulatory concerns, while analysts caution about potential risks from Medicare drug price negotiations. The company is set to release its earnings on July 30, 2026, amid mixed market reactions.

Updated 38m ago · Powered by Yahoo Scout
  • Previous Close 58.56
  • Open 58.69
  • Bid --
  • Ask --
  • Day's Range 57.27 - 58.88
  • 52 Week Range 42.52 - 62.89
  • Volume 11,330,228
  • Avg. Volume 11,513,730
  • Market Cap (intraday) 117.664B
  • Beta (5Y Monthly) 0.24
  • PE Ratio (TTM) 16.14
  • EPS (TTM) 3.57
  • Earnings Date Jul 30, 2026
  • Forward Dividend & Yield 2.52 (4.37%)
  • Ex-Dividend Date Jul 2, 2026
  • 1y Target Est 63.08

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

www.bms.com

32,500

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 6/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BMY
9.20%
S&P 500 (^GSPC)
9.55%

1-Year Return

BMY
30.70%
S&P 500 (^GSPC)
20.86%

3-Year Return

BMY
3.52%
S&P 500 (^GSPC)
68.51%

5-Year Return

BMY
5.42%
S&P 500 (^GSPC)
74.51%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 11.49B
Earnings 3.24B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
2B
4B
6B
8B
10B
12B

Analyst Insights

View More

Analyst Price Targets

40.00 Low
63.08 Average
57.62 Current
75.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/9/2026
Analyst B of A Securities
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 68 -> 67

Statistics

View More

Valuation Measures

Annual
As of 6/30/2026
  • Market Cap

    117.66B

  • Enterprise Value

    153.61B

  • Trailing P/E

    16.14

  • Forward P/E

    9.13

  • PEG Ratio (5yr expected)

    1.50

  • Price/Sales (ttm)

    2.43

  • Price/Book (mrq)

    5.86

  • Enterprise Value/Revenue

    3.17

  • Enterprise Value/EBITDA

    10.24

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.01%

  • Return on Assets (ttm)

    10.69%

  • Return on Equity (ttm)

    38.73%

  • Revenue (ttm)

    48.48B

  • Net Income Avi to Common (ttm)

    7.27B

  • Diluted EPS (ttm)

    3.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.49B

  • Total Debt/Equity (mrq)

    230.97%

  • Levered Free Cash Flow (ttm)

    9.85B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

57.62 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions. BMY shares are a component of the S&P 500.

    Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions. BMY shares are a component of the S&P 500.

    Rating
  • The major indices are broadly higher at midday on Wednesday. Oil prices have plunged on optimism that a peace deal with Iran might be close. Crude oil is down 7% at $95 per barrel. The yield on the 10-year note is at 4.36%, and the VIX volatility index is at 17.

    The major indices are broadly higher at midday on Wednesday. Oil prices have plunged on optimism that a peace deal with Iran might be close. Crude oil is down 7% at $95 per barrel. The yield on the 10-year note is at 4.36%, and the VIX volatility index is at 17.

  • Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions. The company completed its merger with Celgene in November 2019. The BMY shares are a component of the S&P 500.

    Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions. The company completed its merger with Celgene in November 2019. The BMY shares are a component of the S&P 500.

    Rating
  • The war with Iran has entered its seventh week, with the ceasefire entering week two and a first round of peace talks having taken place over the weekend. On Wall Street, earnings season kicks off this week, with banks leading the charge. Last week, the Dow Jones Industrial Average was up 3%, the S&P 500 rose 4%, and the Nasdaq gained 5%. Year to date, all three indices are showing losses, with the Dow down 0.3%, the S&P lower by 0.4%, and the Nasdaq off by 1.5%. On the earnings calendar, Goldman Sachs reports on Monday; JPMorgan Chase, Citigroup, Wells Fargo, BlackRock, and Johnson & Johnson on Tuesday; Bank of America, Morgan Stanley, and PNC Financial on Wednesday; Taiwan Semiconductor, Netflix, PepsiCo, Abbott Labs, Charles Schwab, and Bank of New York Mellon on Thursday; and Truist Financial, Fifth Third Bank, and State Street on Friday. On the economic calendar, this is a light week. Existing Home Sales will be reported on Monday; the Producer Price Index is due out on Tuesday; and new data on Housing Starts and Building Permits hits the tape on Friday. The impact of the war is showing up in economic data. The price for gas jumped another 13 cents and is now at an average of $4.12 per gallon for regular gas. Atlanta Fed GDPNow now forecasts 1.3% growth for 1Q, down from 3.0% about a month ago. The Cleveland Fed Inflation Nowcast calls for CPI of 3.6% in April, up from the 3.3% print for March. Mortgage rates moved lower last week, down nine basis points last week, with the average 30-year fixed-rate mortgage now at 6.37%, according to FreddieMac. The next Federal Open Market Committee (FOMC) meeting is on April 29. Odds have pivoted from a rate cut to a rate hike, although the odds for a move of any kind are low at 2%. President Trump's nominee to be the next Fed chairman, Kevin Warsh, is continues to make his way through the Congressional approval process. After Jerome Powell's term as chairman expires, he will remain on the FOMC. Taking a deeper dive into performance so far in 2026, a leading industrialized global stock market index, the ETF EFA, is up 6% year to date. The leading emerging market ETF (EEM) is up 10% year to date. U.S. growth stocks are down 7% year to date, as per the ETF IWF, while value stocks (IWD) are up 5%. In other asset classes for the year to date, AGG bonds are down 1%, gold is up 10%, crude oil is up 66%, and Bitcoin is down 17%. The U.S. dollar is flat, tracking DXY. The VIX Volatility Index was about 19 on Friday, below its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026 is Energy (+37%), Materials (+9%), Utilities (+8%), Consumer Staples (+7%), Industrials (+4%), Real Estate (+3%), Healthcare (-5%), Communication Services (-7%), Consumer Discretionary (-9%), Financials (-10%), and Information Technology (-12%). By comparison, the S&P 500 is down 0.4% year to date.

    The war with Iran has entered its seventh week, with the ceasefire entering week two and a first round of peace talks having taken place over the weekend. On Wall Street, earnings season kicks off this week, with banks leading the charge. Last week, the Dow Jones Industrial Average was up 3%, the S&P 500 rose 4%, and the Nasdaq gained 5%. Year to date, all three indices are showing losses, with the Dow down 0.3%, the S&P lower by 0.4%, and the Nasdaq off by 1.5%. On the earnings calendar, Goldman Sachs reports on Monday; JPMorgan Chase, Citigroup, Wells Fargo, BlackRock, and Johnson & Johnson on Tuesday; Bank of America, Morgan Stanley, and PNC Financial on Wednesday; Taiwan Semiconductor, Netflix, PepsiCo, Abbott Labs, Charles Schwab, and Bank of New York Mellon on Thursday; and Truist Financial, Fifth Third Bank, and State Street on Friday. On the economic calendar, this is a light week. Existing Home Sales will be reported on Monday; the Producer Price Index is due out on Tuesday; and new data on Housing Starts and Building Permits hits the tape on Friday. The impact of the war is showing up in economic data. The price for gas jumped another 13 cents and is now at an average of $4.12 per gallon for regular gas. Atlanta Fed GDPNow now forecasts 1.3% growth for 1Q, down from 3.0% about a month ago. The Cleveland Fed Inflation Nowcast calls for CPI of 3.6% in April, up from the 3.3% print for March. Mortgage rates moved lower last week, down nine basis points last week, with the average 30-year fixed-rate mortgage now at 6.37%, according to FreddieMac. The next Federal Open Market Committee (FOMC) meeting is on April 29. Odds have pivoted from a rate cut to a rate hike, although the odds for a move of any kind are low at 2%. President Trump's nominee to be the next Fed chairman, Kevin Warsh, is continues to make his way through the Congressional approval process. After Jerome Powell's term as chairman expires, he will remain on the FOMC. Taking a deeper dive into performance so far in 2026, a leading industrialized global stock market index, the ETF EFA, is up 6% year to date. The leading emerging market ETF (EEM) is up 10% year to date. U.S. growth stocks are down 7% year to date, as per the ETF IWF, while value stocks (IWD) are up 5%. In other asset classes for the year to date, AGG bonds are down 1%, gold is up 10%, crude oil is up 66%, and Bitcoin is down 17%. The U.S. dollar is flat, tracking DXY. The VIX Volatility Index was about 19 on Friday, below its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026 is Energy (+37%), Materials (+9%), Utilities (+8%), Consumer Staples (+7%), Industrials (+4%), Real Estate (+3%), Healthcare (-5%), Communication Services (-7%), Consumer Discretionary (-9%), Financials (-10%), and Information Technology (-12%). By comparison, the S&P 500 is down 0.4% year to date.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: